Featured Content
Top Myeloma Journal Articles for the Week of June 28, 2021
Here are the top journal articles from the week of June 24, 2021 as selected by the MYELOMA360 staff. First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness...
Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma
In this webcast, expert faculty discuss best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options. Learners will also get a look ahead at emerging therapeutic strategies and clinical trials...
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Myeloma News
Salvage Therapy for Amyloidosis in Multiple Myeloma: Agents and Anti-Fibril Therapy
Source: Pharmacy Times articles A presentation at the Society of Hematologic Oncology 2021 Annual Meeting reviewed the treatment of amyloidosis in multiple myeloma. Read More
Myeloma research on the move
Source: Myeloma : nature.com subject feeds Post Content Read More
Updates in Sequencing Treatment for Early Multiple Myeloma Relapse
Source: Pharmacy Times articles Presenter Maria-Victoria Mateos, MD, PhD, University Hospital of Salamanca-IBSAL, Salamanca, Spain, discussed how optimal sequencing in MM has changed from those outlined in the older EU guidelines. Read More
Dosing Schedule of Intravenous Bisphosphonate Has Little Effect on Recurrent Skeletal-Related Events in Patients With Multiple Myeloma
Source: Myeloma – Hematology Advisor Fewer administrations of intravenous bisphosphonate among patients with multiple myeloma had comparable rates of recurrent skeletal-related events (SRE) compared with more frequent dosing. These findings, from a retrospective...
Prognostic Importance of Extramedullary Lesions in Multiple Myeloma
Source: Myeloma – Hematology Advisor Researchers conducting a retrospective study identified extramedullary (EM) lesions as a possible indicator of poor prognosis in patients with multiple myeloma (MM) treated in the first line with bortezomib. The study’s results...
Patients With Multiple Myeloma, Shortest Survival Times Have the Most Kidney Damage
Source: Pharmacy Times articles Nearly 20% of patients with multiple myeloma have a form of the disease in which they make high quantities of a component of monoclonal proteins, which damages the kidneys. Read More
Machine Learning Algorithm May Predict Treatment Sensitivity in Multiple Myeloma
Source: Myeloma – Hematology Advisor A machine learning algorithm may help to improve first-line treatment decisions in up to 17% of patients diagnosed with multiple myeloma (MM), according to a paper published in PLoS One. MM is an incurable hematologic cancer with a...
Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition
Source: Myeloma : nature.com subject feeds Post Content Read More
Analyzing Minimal Residual Disease for Patients With Multiple Myeloma
Source: Myeloma – Hematology Advisor Targeted and immune therapies to treat multiple myeloma (MM) are advancing rapidly, and minimal residual disease (MRD) negativity is possible across the disease spectrum. MRD may be a surrogate endpoint for patient outcomes in...
A Case of Multiple Myeloma Presenting With Ophthalmic Changes
Source: Myeloma – Hematology Advisor Researchers in Brazil presented a case report in the journal Case Reports in Ophthalmology of a patient with multiple myeloma (MM) who developed immunogammopathy maculopathy and hyperviscosity syndrome (HVS)-related retinopathy....
Recent Publications
Vertebroplasty in patients with multiple myeloma with vertebral compression fractures: protocol for a single-blind randomised controlled trial
BMJ Open. 2021 Sep 6;11(9):e045854. doi: 10.1136/bmjopen-2020-045854.ABSTRACTINTRODUCTION: Multiple myeloma (MM) is a plasma cell cancer where about 1/3 of the patients present with pathological fractures at the time of diagnosis. Despite treatment, the majority of...
Analysis of Mesencephalic Astrocyte-derived Neurotrophic Factor in Multiple Myeloma
Anticancer Res. 2021 Sep;41(9):4305-4312. doi: 10.21873/anticanres.15235.ABSTRACTBACKGROUND/AIM: Multiple myeloma (MM) is characterized by high production of immunoglobulins resulting in a constant source of endoplasmic reticulum (ER)-stress. Mesencephalic...
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1
Blood Adv. 2021 Aug 24;5(16):3203-3215. doi: 10.1182/bloodadvances.2021004976.ABSTRACTSomatic mutations in UBA1 involving hematopoietic stem and myeloid cells have been reported in patients with the newly defined VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory,...
Role of whole-body diffusion-weighted imaging in evaluation of multiple myeloma
Medicine (Baltimore). 2021 Sep 3;100(35):e27131. doi: 10.1097/MD.0000000000027131.ABSTRACTThe evaluation of bone disease in multiple myeloma (MM) is an important topic in imaging. This study retrospectively investigated whole-body diffusion-weighted imaging (WB-DWI)...
Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime
Orv Hetil. 2021 Sep 5;162(36):1451-1458. doi: 10.1556/650.2021.32179.ABSTRACTÖsszefoglaló. Bevezetés: A myeloma multiplex mindmáig alapvetően gyógyíthatatlan betegség, ezért nagy klinikai jelentőségük van az eredményes mentő kezeléseknek. A szájon át adható első...
Effect of the uncoupling protein-2 (UCP-2) and nuclear receptor subfamily 3 group C member 1 (NR3C1) genes on treatment efficacy and survival in patients with multiple myeloma: a single-center study
BMC Res Notes. 2021 Sep 4;14(1):346. doi: 10.1186/s13104-021-05758-7.ABSTRACTOBJECTIVE: Studies on the genetic background of patients with multiple myeloma (MM) have been increasing; two important factors considered in such works are uncoupling protein-2 (UCP-2) and...
Analysis of seven cases of multiple myeloma with initial manifestation of bleeding
Zhonghua Nei Ke Za Zhi. 2021 Sep 1;60(9):831-833. doi: 10.3760/cma.j.cn112138-20200828-00780.ABSTRACTA retrospective analysis of 7 patients of multiple myeloma (MM) with initial manifestation of bleeding and coagulation abnormalities were performed. Clinical...
Prediction of Long Bone Fractures in Multiple Myeloma Patients in an Advanced Imaging World
Isr Med Assoc J. 2021 Aug;23(8):501-505.ABSTRACTBACKGROUND: Multiple myeloma (MM) affects the long bones in 25% of patients. The advent of positron-emission tomography/computed tomography (PET/CT) scanners offers the possibility of both metabolic and radiographic...
